SML2811
Phenanthriplatin
>97% (NMR)
别名:
(SP-4-3)-Diamminechlorido(phenanthridine)platinum(II) nitrate, PhenPt, cis-[Pt(NH3)2(phenanthridine)Cl]NO3
跳至
品質等級
化驗
>97% (NMR)
形狀
powder
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
2-8°C
SMILES 字串
Cl[Pt](N)([N+]1=C2C=CC=CC2=C3C=CC=CC3=C1)N.[O-][N+]([O-])=O
InChI 密鑰
BELJCNWNXQVJPZ-UHFFFAOYSA-M
1 of 4
此商品 | SML2556 | SML1062 | SML2298 |
|---|---|---|---|
| assay >97% (NMR) | assay >97% (NMR) | assay ≥98% (HPLC) | assay ≥97% (HPLC) |
| form powder | form powder | form powder | form powder |
| Quality Level 100 | Quality Level - | Quality Level 100 | Quality Level - |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| solubility DMSO: 2 mg/mL, clear | solubility DMSO: 0.2 mg/mL (warmed) | solubility DMSO: 20 mg/mL, clear | solubility DMSO: 2 mg/mL, clear |
| color white to beige | color faint yellow to dark orange | color white to brown | color white to beige |
生化／生理作用
Cationic monofunctional DNA-binding platinum (II) complex with significantly greater anticancer activity than cisplatin, oxaliplatin, and pyriplatin.
Phenanthriplatin is a cationic monofunctional DNA-binding platinum (II) complex with significantly greater anticancer activity (IC50 in μM = 0.035/Ntera2, 0.22/A549, 0.30/HeLa, 0.59/U2OS, 0.74/PC3, 0.94/MCF7, 2.02/HT29; 72 h, MTT assay) than cisplatin, oxaliplatin, and pyriplatin. Enhanced cellular uptake due to its hydrophobic phenanthridine ligand as well as more rapid DNA covalent-binding activity both contribute to its superior anticancer efficacy. Phenanthriplatin binds more effectively to 5′-deoxyguanosine monophosphate than to N-acetyl methionine, whereas pyriplatin reacts equally to both.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
Daniele Veclani et al.
Journal of the American Chemical Society, 140(43), 14024-14027 (2018-09-07)
The monofunctional platinum drug phenanthriplatin (phenPt) blocks the replication of cancer cells even if it reacts with only one guanine base. However, there is still insufficient experimental data to improve its cytotoxicity and all previously proposed chemical modifications of the
Jerry D Monroe et al.
PloS one, 13(3), e0192505-e0192505 (2018-03-08)
Unlike cisplatin, which forms bifunctional DNA adducts, monofunctional platinum(II) complexes bind only one strand of DNA and might target cancer without causing auditory side-effects associated with cisplatin treatment. We synthesized the monofunctional triamine-ligated platinum(II) complexes, Pt(diethylenetriamine)Cl, [Pt(dien)Cl]+, and Pt(N,N-diethyldiethylenetriamine)Cl, [Pt(Et2dien)Cl]+
Amit A Vernekar et al.
Journal of the American Chemical Society, 140(12), 4279-4287 (2018-03-20)
Efficient loading of drugs in novel delivery agents has the potential to substantially improve therapy by targeting the diseased tissue while avoiding unwanted side effects. Here we report the first systematic study of the loading mechanism of phenanthriplatin and its
Matthew W Kellinger et al.
Journal of the American Chemical Society, 135(35), 13054-13061 (2013-08-10)
Transcription inhibition by platinum anticancer drugs is an important component of their mechanism of action. Phenanthriplatin, a cisplatin derivative containing phenanthridine in place of one of the chloride ligands, forms highly potent monofunctional adducts on DNA having a structure and
Wen Zhou et al.
Chemical communications (Cambridge, England), 54(22), 2788-2791 (2018-02-28)
A trans-DDP based monofunctional phenanthridine Pt(ii) complex was synthesized and characterized. Its anticancer activity was studied in vitro on a panel of human cancer cell lines and mouse intestinal cancer organoids. This complex displays significant antitumor properties, with a different
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持